Raras
Buscar doenças, sintomas, genes...
Síndromes mielodisplásicos
ORPHA:52688CID-10 · D46OMIM 614286DOENÇA RARA

É uma doença do sangue que surge de uma célula-mãe alterada, gerando um grupo de células "iguais" (clonais) e problemáticas. Ela se caracteriza pela produção de células sanguíneas com formato e função anormais (displasia), e por uma formação ineficaz de novas células do sangue em um ou mais tipos (como glóbulos vermelhos, brancos ou plaquetas). Essa alteração nas células pode vir junto com um aumento nas células jovens da medula óssea (chamadas mieloblastos). No entanto, a quantidade dessas células é sempre inferior a 20%. Se fosse igual ou superior a 20%, a Organização Mundial da Saúde (OMS) classificaria a condição como leucemia mieloide aguda. A doença pode surgir espontaneamente (sem uma causa aparente) ou ser resultado da exposição a certos medicamentos (como alguns usados em quimioterapia) e/ou radioterapia.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

É uma doença do sangue que surge de uma célula-mãe alterada, gerando um grupo de células "iguais" (clonais) e problemáticas. Ela se caracteriza pela produção de células sanguíneas com formato e função anormais (displasia), e por uma formação ineficaz de novas células do sangue em um ou mais tipos (como glóbulos vermelhos, brancos ou plaquetas). Essa alteração nas células pode vir junto com um aumento nas células jovens da medula óssea (chamadas mieloblastos). No entanto, a quantidade dessas células é sempre inferior a 20%. Se fosse igual ou superior a 20%, a Organização Mundial da Saúde (OMS) classificaria a condição como leucemia mieloide aguda. A doença pode surgir espontaneamente (sem uma causa aparente) ou ser resultado da exposição a certos medicamentos (como alguns usados em quimioterapia) e/ou radioterapia.

Pesquisas ativas
30 ensaios
2612 total registrados no ClinicalTrials.gov
Publicações científicas
14.591 artigos
Último publicado: 2026 Apr 17

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
7.0
Germany
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: D46
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🩸
Sangue
18 sintomas
🦴
Ossos e articulações
13 sintomas
🫁
Pulmão
4 sintomas
❤️
Coração
3 sintomas
😀
Face
3 sintomas
🧬
Pele e cabelo
3 sintomas

+ 34 sintomas em outras categorias

Características mais comuns

Trigonocefalia
HP:0001442
Dispneia de esforço
Palpitações
Febre
Palidez anêmica
89sintomas
Sem dados (89)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 89 características clínicas mais associadas, ordenadas por frequência.

TrigonocefaliaTrigonocephaly
HP:0001442
Dispneia de esforçoExertional dyspnea
PalpitaçõesPalpitations
FebreFever

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico14.591PubMed
Últimos 10 anos200publicações
Pico2026139 papers
Linha do tempo
2026Hoje · 2026🧪 1975Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

10 genes identificados com associação a esta condição.

TP53Cellular tumor antigen p53Major susceptibility factor inAltamente restrito
FUNÇÃO

Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apop

LOCALIZAÇÃO

CytoplasmNucleusNucleus, PML bodyEndoplasmic reticulumMitochondrion matrixCytoplasm, cytoskeleton, microtubule organizing center, centrosome

VIAS BIOLÓGICAS (10)
TP53 Regulates Metabolic GenesRegulation of TP53 ExpressionRegulation of TP53 DegradationOncogene Induced SenescenceOxidative Stress Induced Senescence
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
73.0 TPM
Skin Sun Exposed Lower leg
37.0 TPM
Skin Not Sun Exposed Suprapubic
35.2 TPM
Fibroblastos
32.9 TPM
Ovário
32.4 TPM
OUTRAS DOENÇAS (29)
Li-Fraumeni syndromenasopharyngeal carcinoma, susceptibility to, 1hepatocellular carcinomafamilial pancreatic carcinoma
HGNC:11998UniProt:P04637
GATA2Endothelial transcription factor GATA-2Candidate gene tested inAltamente restrito
FUNÇÃO

Transcriptional activator which regulates endothelin-1 gene expression in endothelial cells. Binds to the consensus sequence 5'-AGATAG-3'

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (3)
RUNX1 regulates transcription of genes involved in differentiation of HSCsTranscriptional regulation of granulopoiesisFactors involved in megakaryocyte development and platelet production
MECANISMO DE DOENÇA

Immunodeficiency 21

An immunodeficiency disease characterized by profoundly decreased or absent monocytes, B-lymphocytes, natural killer lymphocytes, and circulating and tissue dendritic cells, with little or no effect on T-cell numbers. Clinical features of DCML include susceptibility to disseminated non-tuberculous mycobacterial infections, papillomavirus infections, opportunistic fungal infections, and pulmonary alveolar proteinosis. Bone marrow hypocellularity and dysplasia of myeloid, erythroid, and megakaryocytic lineages are present in most patients, as are karyotypic abnormalities, including monosomy 7 and trisomy 8. This syndrome links susceptibility to mycobacterial, viral, and fungal infections with malignancy and can be transmitted in an autosomal dominant pattern.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
86.1 TPM
Próstata
69.7 TPM
Cervix Endocervix
65.8 TPM
Cervix Ectocervix
62.1 TPM
Fallopian Tube
57.5 TPM
OUTRAS DOENÇAS (4)
deafness-lymphedema-leukemia syndromemonocytopenia with susceptibility to infectionsacute myeloid leukemiamyelodysplastic syndrome
HGNC:4171UniProt:P23769
MYSM1Deubiquitinase MYSM1Candidate gene tested inRestrito
FUNÇÃO

Metalloprotease with deubiquitinase activity that plays important regulator roles in hematopoietic stem cell function, blood cell production and immune response (PubMed:24062447, PubMed:26220525, PubMed:28115216). Participates in the normal programming of B-cell responses to antigen after the maturation process (By similarity). Within the cytoplasm, plays critical roles in the repression of innate immunity and autoimmunity (PubMed:33086059). Removes 'Lys-63'-linked polyubiquitins from TRAF3 and

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (1)
Metalloprotease DUBs
MECANISMO DE DOENÇA

Bone marrow failure syndrome 4

A form of bone marrow failure syndrome, a heterogeneous group of life-threatening disorders characterized by hematopoietic defects in association with a range of variable extra-hematopoietic manifestations. BMFS4 is characterized by early-onset anemia, leukopenia, decreased B cells, and developmental aberrations including facial dysmorphism, mild skeletal anomalies, and neurodevelopmental delay. BMFS4 inheritance is autosomal recessive.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
31.8 TPM
Útero
29.7 TPM
Ovário
28.4 TPM
Cervix Ectocervix
27.9 TPM
Cervix Endocervix
26.8 TPM
OUTRAS DOENÇAS (2)
bone marrow failure syndrome 4congenital progressive bone marrow failure-B-cell immunodeficiency-skeletal dysplasia syndrome
HGNC:29401UniProt:Q5VVJ2
SF3B1Splicing factor 3B subunit 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Component of the 17S U2 SnRNP complex of the spliceosome, a large ribonucleoprotein complex that removes introns from transcribed pre-mRNAs (PubMed:12234937, PubMed:27720643, PubMed:32494006, PubMed:34822310, PubMed:36104565). The 17S U2 SnRNP complex (1) directly participates in early spliceosome assembly and (2) mediates recognition of the intron branch site during pre-mRNA splicing by promoting the selection of the pre-mRNA branch-site adenosine, the nucleophile for the first step of splicing

LOCALIZAÇÃO

NucleusNucleus speckle

VIAS BIOLÓGICAS (5)
Dengue Virus-Host InteractionsmRNA Splicing - Major PathwaymRNA PolyadenylationmRNA Splicing - Minor PathwayB-WICH complex positively regulates rRNA expression
EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
245.2 TPM
Útero
235.8 TPM
Ovário
231.2 TPM
Cervix Ectocervix
226.6 TPM
Baço
211.5 TPM
OUTRAS DOENÇAS (3)
myelodysplastic syndromeuveal melanomamyelodysplastic syndrome with ring sideroblasts
HGNC:10768UniProt:O75533
GNB1Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems (PubMed:29925951, PubMed:33762731, PubMed:34239069, PubMed:35610220, PubMed:35714614, PubMed:35835867, PubMed:36087581, PubMed:36989299, PubMed:37327704, PubMed:37935376, PubMed:37935377, PubMed:37963465, PubMed:37991948, PubMed:38168118, PubMed:38552625). The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G prot

LOCALIZAÇÃO

VIAS BIOLÓGICAS (10)
Extra-nuclear estrogen signalingGPER1 signalingThromboxane signalling through TP receptorADORA2B mediated anti-inflammatory cytokines productionProstacyclin signalling through prostacyclin receptor
MECANISMO DE DOENÇA

Intellectual developmental disorder, autosomal dominant 42

A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD42 patients manifest global developmental delay commonly accompanied by hypotonia, seizures of various types, ophthalmological manifestations, and poor growth.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
395.8 TPM
Cérebro - Hemisfério cerebelar
371.2 TPM
Fibroblastos
327.2 TPM
Córtex cerebral
325.9 TPM
Brain Anterior cingulate cortex BA24
308.4 TPM
OUTRAS DOENÇAS (3)
leukemia, acute lymphocytic, susceptibility to, 1myelodysplastic syndromeintellectual disability, autosomal dominant 42
HGNC:4396UniProt:P62873
SAMD9Sterile alpha motif domain-containing protein 9Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Double-stranded nucleic acid binding that acts as an antiviral factor by playing an essential role in the formation of cytoplasmic antiviral granules (PubMed:25428864, PubMed:28157624). May play a role in the inflammatory response to tissue injury and the control of extra-osseous calcification, acting as a downstream target of TNF signaling. Involved in the regulation of EGR1, in coordination with RGL2. May be involved in endosome fusion

LOCALIZAÇÃO

Cytoplasm

MECANISMO DE DOENÇA

Tumoral calcinosis, normophosphatemic, familial

An uncommon, life-threatening disorder characterized by progressive deposition of calcified masses in cutaneous and subcutaneous tissues. Serum phosphate levels are normal. Clinical features include painful calcified ulcerative lesions and massive calcium deposition in the mid- and lower dermis, severe skin and bone infections, erythematous papular skin eruption in infancy, conjunctivitis, and gingivitis. NFTC shows a striking resemblance to acquired dystrophic calcinosis, in which tissue calcification occurs as a consequence of tissue injury/inflammation.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
35.1 TPM
Linfócitos
20.1 TPM
Baço
16.0 TPM
Fibroblastos
11.7 TPM
Vagina
10.4 TPM
OUTRAS DOENÇAS (3)
MIRAGE syndromemonosomy 7 myelodysplasia and leukemia syndrome 2normophosphatemic familial tumoral calcinosis
HGNC:1348UniProt:Q5K651
SAMD9LSterile alpha motif domain-containing protein 9-likeDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in endosome fusion. Mediates down-regulation of growth factor signaling via internalization of growth factor receptors

LOCALIZAÇÃO

Early endosomeMitochondrion

MECANISMO DE DOENÇA

Ataxia-pancytopenia syndrome

An autosomal dominant disorder characterized by cerebellar ataxia, variable hematologic cytopenias, and predisposition to bone marrow failure and myeloid leukemia.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
55.2 TPM
Baço
34.1 TPM
Pulmão
22.9 TPM
Nervo tibial
17.2 TPM
Cervix Endocervix
14.3 TPM
OUTRAS DOENÇAS (4)
monosomy 7 myelodysplasia and leukemia syndrome 1ataxia-pancytopenia syndromespinocerebellar ataxia 49SAMD9L-associated autoinflammatory syndrome
HGNC:1349UniProt:Q8IVG5
TET2Methylcytosine dioxygenase TET2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in active DNA demethylation. Has a preference for 5-hydroxymethylcytosine in CpG motifs. Also mediates subsequent conversion of 5hmC into 5-formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine (5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probably constitutes the first step in cytosine demethylation. Methylation at the C5 position

LOCALIZAÇÃO

NucleusChromosome

VIAS BIOLÓGICAS (2)
TET1,2,3 and TDG demethylate DNASpecification of primordial germ cells
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
12.3 TPM
Cervix Ectocervix
10.8 TPM
Vagina
10.4 TPM
Skin Not Sun Exposed Suprapubic
10.3 TPM
Skin Sun Exposed Lower leg
10.2 TPM
OUTRAS DOENÇAS (11)
myelodysplastic syndromeimmunodeficiency 75acute myeloid leukemia with multilineage dysplasiamyelodysplastic syndrome with ring sideroblasts
HGNC:25941UniProt:Q6N021
RPS14Small ribosomal subunit protein uS11Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Component of the small ribosomal subunit. The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell. Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and c

LOCALIZAÇÃO

CytoplasmNucleus, nucleolus

VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsMajor pathway of rRNA processing in the nucleolus and cytosolSARS-CoV-2 modulates host translation machinerySARS-CoV-1 modulates host translation machineryViral mRNA Translation
EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
1372.4 TPM
Linfócitos
1292.4 TPM
Skin Sun Exposed Lower leg
1008.0 TPM
Skin Not Sun Exposed Suprapubic
995.1 TPM
Cervix Ectocervix
953.5 TPM
OUTRAS DOENÇAS (1)
myelodysplastic syndrome associated with isolated del(5q)
HGNC:10387UniProt:P62263
ASXL1Polycomb group protein ASXL1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Probable Polycomb group (PcG) protein involved in transcriptional regulation mediated by ligand-bound nuclear hormone receptors, such as retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor gamma (PPARG) (PubMed:16606617). Acts as a coactivator of RARA and RXRA through association with NCOA1 (PubMed:16606617). Acts as a corepressor for PPARG and suppresses its adipocyte differentiation-inducing activity (By similarity). Non-catalytic component of the PR-DUB complex, a co

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
UCH proteinases
MECANISMO DE DOENÇA

Bohring-Opitz syndrome

A syndrome characterized by severe intrauterine growth retardation, poor feeding, profound intellectual disability, trigonocephaly, prominent metopic suture, exophthalmos, nevus flammeus of the face, upslanting palpebral fissures, hirsutism, and flexion of the elbows and wrists with deviation of the wrists and metacarpophalangeal joints.

VIAS REACTOME (1)
OUTRAS DOENÇAS (6)
myelodysplastic syndromeBohring-Opitz syndromeaggressive systemic mastocytosisacute myeloid leukemia with multilineage dysplasia
HGNC:18318UniProt:Q8IXJ9

Medicamentos aprovados (FDA)

3 medicamentos encontrados nos registros da FDA americana.

💊 AZACITIDINE (AZACITIDINE FOR)
💊 Eltrombopag Olamine (ELTROMBOPAG)
💊 Azacitidine (AZACITIDINE)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

2,171 variantes patogênicas registradas no ClinVar.

🧬 TP53: NM_000546.6(TP53):c.377del (p.Tyr126fs) ()
🧬 TP53: NM_000546.6(TP53):c.494dup (p.Ser166fs) ()
🧬 TP53: NM_000546.6(TP53):c.184_187dup (p.Ala63fs) ()
🧬 TP53: NM_000546.6(TP53):c.549dup (p.Asp184fs) ()
🧬 TP53: NM_000546.6(TP53):c.43del (p.Ser15fs) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 86 variantes classificadas pelo ClinVar.

47
39
Patogênica (54.7%)
VUS (45.3%)
VARIANTES MAIS SIGNIFICATIVAS
SF3B1: NM_012433.4(SF3B1):c.1866G>C (p.Glu622Asp) [Likely pathogenic]
GATA2: NM_032638.5(GATA2):c.46del (p.Val16fs) [Pathogenic/Likely pathogenic]
TET2: NM_001127208.3(TET2):c.797del (p.His266fs) [Likely pathogenic]
GATA2: NM_032638.5(GATA2):c.345del (p.Trp116fs) [Likely pathogenic]
EEF1D: NM_001130053.5(EEF1D):c.1488+1G>A [Likely pathogenic]

Vias biológicas (Reactome)

93 vias biológicas associadas aos genes desta condição.

Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ub-specific processing proteases Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation RUNX1 regulates transcription of genes involved in differentiation of HSCs Transcriptional regulation of granulopoiesis Factors involved in megakaryocyte development and platelet production Metalloprotease DUBs B-WICH complex positively regulates rRNA expression mRNA Splicing - Major Pathway mRNA Splicing - Minor Pathway mRNA Polyadenylation Dengue Virus-Host Interactions Activation of G protein gated Potassium channels Glucagon signaling in metabolic regulation G-protein activation Activation of the phototransduction cascade Inactivation, recovery and regulation of the phototransduction cascade Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Olfactory Signaling Pathway Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) ADP signalling through P2Y purinoceptor 12 G beta:gamma signalling through PI3Kgamma Prostacyclin signalling through prostacyclin receptor Adrenaline,noradrenaline inhibits insulin secretion Ca2+ pathway G alpha (q) signalling events G alpha (12/13) signalling events G beta:gamma signalling through PLC beta G alpha (s) signalling events ADP signalling through P2Y purinoceptor 1 G alpha (i) signalling events G alpha (z) signalling events Glucagon-type ligand receptors Thromboxane signalling through TP receptor Vasopressin regulates renal water homeostasis via Aquaporins Thrombin signalling through proteinase activated receptors (PARs) Presynaptic function of Kainate receptors Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding G beta:gamma signalling through BTK G beta:gamma signalling through CDC42 Extra-nuclear estrogen signaling GPER1 signaling TET1,2,3 and TDG demethylate DNA Specification of primordial germ cells L13a-mediated translational silencing of Ceruloplasmin expression Peptide chain elongation SRP-dependent cotranslational protein targeting to membrane Viral mRNA Translation Selenocysteine synthesis rRNA modification in the nucleus and cytosol Major pathway of rRNA processing in the nucleolus and cytosol Translation initiation complex formation Formation of a pool of free 40S subunits Formation of the ternary complex, and subsequently, the 43S complex Ribosomal scanning and start codon recognition GTP hydrolysis and joining of the 60S ribosomal subunit Eukaryotic Translation Termination Regulation of expression of SLITs and ROBOs Response of EIF2AK4 (GCN2) to amino acid deficiency SARS-CoV-1 modulates host translation machinery SARS-CoV-2 modulates host translation machinery Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA UCH proteinases

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 213
1Fase 13
·Pré-clínico4
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndromes mielodisplásicos

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

20 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT06303193 · Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FL…Recrutando
PHASE1, PHASE2
NCT05564390 · MYELOMATCH: A Screening Study to Assign People With Myeloid …Recrutando
PHASE2
NCT06247787 · A Study to Find the Highest Dose of Imetelstat in Combinatio…Recrutando
PHASE1
NCT05969860 · At-Home Cancer Directed Therapy Versus in Clinic for the Tre…Recrutando
PHASE2
NCT07532824 · Proton-Based Total Marrow Irradiation for Allogeneic Transpl…Recrutando
PHASE1, PHASE2
NCT07493538 · MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation…Recrutando
PHASE2
NCT04493138 · Azacitidine and Quizartinib for the Treatment of Myelodyspla…Recrutando
PHASE1, PHASE2
NCT06439199 · Biological, Prospective Study Evaluating the Dosage of Plasm…Recrutando
NCT01624805 · Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclospor…Recrutando
PHASE2
NCT06597734 · A Phase 2 Study Evaluating Olutasidenib in Combination With …Recrutando
PHASE2
NCT07400341 · Romiplostim Versus rhTPO for Platelet Engraftment After Tran…Recrutando
PHASE2
NCT06839456 · Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Vira…Recrutando
PHASE1, PHASE2
NCT07500753 · A Single-arm, Prospective Study of a Clad-LABU Conditioning …Recrutando
NA
NCT07216443 · Trial of Orca-T Following Reduced Intensity or Nonmyeloablat…Recrutando
PHASE2
NCT00900198 · Collection of Tissue Samples for Cancer ResearchRecrutando
NCT03896269 · CPX-351 in Treating Patients With Relapsed or Refractory Hig…Recrutando
PHASE1
NCT04771130 · A Study of BGB-11417 in Participants With Myeloid Malignanci…Recrutando
PHASE1, PHASE2
NCT02392572 · ONC201 in Treating Patients With Relapsed or Refractory Acut…Recrutando
PHASE1, PHASE2
NCT06146257 · A Study of GLB-001 in Patients With Relapsed or Refractory A…Recrutando
PHASE1
NCT00923442 · Biology Studies of Hematologic CancersPor convite

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
6.870 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 6.870

#1

RNF25 confers mRNA damage tolerance by curbing activation of the integrated stress response.

Molecular cell2026 Mar 23

Excessive RNA damage activates cellular stress responses, triggering cell death. However, pathways that negatively regulate RNA damage responses are largely uncharacterized. Using genetic screens, we find that the ubiquitin ligase RNF25 provides tolerance to RNA damage caused by the nucleoside analogue azacytidine, a chemotherapeutic agent used to treat acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Mechanistically, we show that azacytidine is incorporated into mRNA, where it causes lesions that stall elongating ribosomes, leading to cytotoxic activation of the GCN2-dependent integrated stress response (ISR). Furthermore, we establish that RNF25 prevents ISR hyperactivation by ubiquitylation of ribosomal protein eS31, thereby suppressing cell death upon azacytidine treatment. Our study reveals an mRNA damage tolerance mechanism that determines cellular survival in response to azacytidine, highlighting RNA damage-induced stress response as a potentially critical component of chemosensitivity in AML and MDS.

#2

Impact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.

Transplantation and cellular therapy2026 Mar 19

The hematopoietic cell transplant comorbidity index (HCT-CI) is a validated prognostic tool for baseline assessment in allogeneic hematopoietic cell transplantation (HCT). The impact of the individual components of the HCT-CI on prognosis remains unknown for patients undergoing post-transplant cyclophosphamide (PTCY) based graft versus host disease (GVHD) prophylaxis. Data were collected and validated from patients undergoing HCT for myelodysplastic syndrome or acute myeloid leukemia at our center between 2018 and 2022. Multivariable regression analysis was used to identify an optimized subset of HCT-CI; Akaike information index (AIC) was used to assess model fit; C-index was used to evaluate the predictive ability of models. From 586, 184 (31%) received PTCY; HCT-CI comorbidities were balanced between non-PTCY and PTCY- subgroups except for renal, which was only present in 8 patients. Higher HCT-CI was associated with an increased cumulative incidence of NRM in univariable (3-year NRM: 22% (≥ 5) vs 12% (2-4) vs 4.8% (0-1), p=0.0002) and multivariable analysis (subdistribution HR 4.28 for HCT-CI≥ 5, p=0.0003, 2.61 for 2-4, p=0.013). Subset of HCT-CI comorbidities-diabetes, infection, peptic ulcer disease, renal, rheumatologic, and severe pulmonary comorbidities- had a similar impact on NRM as the total score. Diabetes and cardiac comorbidities had a strong association with NRM, and the addition of cardiac comorbidities improved the C-index only in the PTCY subgroup. The HCT-CI retains prognostic significance in the PTCY era, although refinement may be required. Future studies can identify links between cardiac comorbidities and NRM when using PTCY.

#3

Effect of Somatic Variants Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Hematology/oncology and stem cell therapy2026 Mar 13

Measurable residual disease (MRD) has established prognostic significance in patients with myeloid disorders; however, there is limited data regarding its prognostic and predictive value and the optimal technique for measurement in the setting of post allogeneic hematopoietic cell transplantation (allo-HCT). A multi-gene next generation sequencing (NGS) panel can overcome the limitations of conventional techniques for measurement of MRD and can shed light onto the longitudinal evolution and genomic complexity of patients undergoing allo-HCT for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In this study, patients with AML or MDS who underwent their first allo-HCT and completed NGS testing at day +100 and were in a state of morphological remission were identified from the transplant registry of Mayo Clinic in Florida. The primary aim was to evaluate the prognostic impact of somatic variants detected via NGS at day +100 post allo-HCT on long-term outcomes. In total, 105 patients who underwent allo-HCT for AML and MDS and completed NGS testing on day +100 were included in the study population. Seventeen patients were found to have detectable variants, and 88 patients were without a detectable variant. At a median follow up of 1.4 years (0.1-5.5), presence of any variant at day +100 was associated with inferior 4-year overall survival (OS) (32% vs. 69%, P < 0.001), decreased progression free survival (PFS) (34% vs. 61%, P < 0.001), and a higher incidence of relapse (64% vs. 23%, P < 0.001). In univariate models, a lower Karnofsky performance score and presence of variants post allo-HCT remained significantly associated with inferior OS, higher relapse incidence, and a decreased PFS. The presence of variants at day +100 post allo-HCT remained significant in multivariate models for relapse (P = 0.002) but not for OS (P = 0.06) and PFS (P = 0.08). These results indicate that the presence of detectable somatic variants at day +100 is associated with poor long-term outcomes and are predictive of a higher incidence of relapse.

#4

Aberrant Kupffer-like differentiation of hematopoietic stem cell is critical for the MDS pathogenesis in Setd2-deficient mice.

Cell death and differentiation2026 Mar 17

Histone methyltransferase SETD2 is recurrently mutated in hematopoietic malignancies. Our previous study showed that Setd2 deficiency impairs the self-renewal potential of murine hematopoietic stem cells (HSCs) and drives myelodysplastic syndrome (MDS)-like disorders. However, the precise oncogenic advantages conferred upon HSCs by Setd2 loss remain unclear. In this study, we found that Setd2 deficiency disrupted the fidelity of HSC lineage differentiation with preferential erythroid commitment and excessive macrophage priming, leading to ineffective erythropoiesis and the production of inflammatory embryonic-derived Kupffer cell (EmKC)-like cells. Notably, these EmKC-like cells exhibited HSC-independent self-renewal capability and remotely perturbed intramedullary hematopoiesis by inducing systemic inflammation. Furthermore, macrophage depletion effectively alleviated the inflammatory state and relieved MDS-like symptoms. Mechanistically, Setd2 loss leads to significant changes in DNA methylation and chromatin accessibility, resulting in the activation of Irf8. These findings suggest that the long-lived inflammatory cells may compensate for the HSC self-renewal defects, triggering systemic inflammation and driving hematopoietic malignant transformation. This paradigm provides a new understanding of hematopoietic malignancies with functional defects and exhaustion of HSCs.

#5

Application of next-generation sequencing in the treatment of myelodysplastic syndrome: from mechanisms to clinical practice.

Blood science (Baltimore, Md.)2026 Jun

Myelodysplastic syndrome (MDS) is a malignant clonal disorder originating from hematopoietic stem and progenitor cells and is characterized by ineffective hematopoiesis and a high propensity for transformation into acute leukemia. Research has indicated that the pathogenesis of MDS is closely linked to genetic mutations and that its progression may encompass multiple stages, including cytogenetic and molecular alterations, leading to the acquisition of oncogenic mutations. The widespread application of next-generation sequencing (NGS) technologies, including whole-genome sequencing, whole-exome sequencing, and RNA sequencing, has significantly improved our understanding of the genetic alterations and transcriptomic modifications underlying MDS. These technologies not only deepen our understanding of molecular mechanisms but also facilitate the identification of potential therapeutic targets and prognostic biomarkers. Consequently, the 2022 World Health Organization Classification and the International Consensus Classification have incorporated molecular features into the MDS classification system, and the Molecular International Prognostic Scoring System (IPSS-M) was introduced. This review aims to summarize the role of NGS in the precise diagnosis, classification, risk assessment, treatment selection, and evaluation of therapeutic effectiveness in MDS, with implications for advancing precision medicine in hematological malignancies.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC6.634 artigos no totalmostrando 199

2026

RNF25 confers mRNA damage tolerance by curbing activation of the integrated stress response.

Molecular cell
2026

A complete blood count-based machine learning model for rapid differentiation of aplastic anemia, immune thrombocytopenia, and myelodysplastic syndromes in routine clinical practice.

Practical laboratory medicine
2026

Impact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.

Transplantation and cellular therapy
2026

Myelodysplastic Syndrome Secondary to Chimeric Antigen Receptor T-cell (CAR-T) Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma.

Cureus
2026

Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study.

Clinical lymphoma, myeloma &amp; leukemia
2026

[Mutation characteristics and prognosis of patients with Fanconi anemia signaling pathway gene mutation myeloproliferative neoplasm].

Zhonghua yi xue za zhi
2026

Emergence and continuous clonal evolution of a JAK2 exon 12-mutated myeloid clone after treatment for de novo acute myeloid leukemia.

Leukemia research
2026

Hematopoietic Stem Cell Transplantation in a Fontan Patient With Myelodysplastic Syndrome.

JACC. Case reports
2026

Effect of Somatic Variants Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Hematology/oncology and stem cell therapy
2026

Aberrant Kupffer-like differentiation of hematopoietic stem cell is critical for the MDS pathogenesis in Setd2-deficient mice.

Cell death and differentiation
2026

Association between red cell distribution width to albumin ratio and all-cause mortality in critically ill patients with myelodysplastic syndrome: a retrospective cohort study.

Hematology (Amsterdam, Netherlands)
2026

[Efficacy and safety of romiplostim N01 for refractory aplastic anemia: a retrospective single-center study].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
2026

Hidden morphological clues in deceptive bone marrow pathologies.

Annales de biologie clinique
2026

Large-Vessel Vasculitis With Autoimmune Myelodysplastic Syndrome: An Uncommon Case of Large-Vessel Vasculitis With Cytopenia That Is Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic Syndrome (VEXAS) Negative.

Cureus
2026

Successful Treatment of Cutaneous Squamous Cell Carcinoma Complicated by Myelodysplastic Syndrome Using Combined ALA-PDT and Narrow-Margin Excision: A Case Report.

Clinical case reports
2026

Seven-Year Course of Hypoplastic Myelodysplastic Syndrome Unmasked by Secondary and Neurological Syphilis.

Mediterranean journal of hematology and infectious diseases
2026

Application of next-generation sequencing in the treatment of myelodysplastic syndrome: from mechanisms to clinical practice.

Blood science (Baltimore, Md.)
2026

Extensive Oral Ulcerations After Stem Cell Transplant.

JAMA oncology
2026

MDS/AML-associated DDX41 helicase facilitates homologous recombination repair by potentially resolving R-loops.

Nucleic acids research
2026

Presumed tumor-infiltrating clonal hematopoiesis unmasking a concomitant systemic mastocytosis with associated myeloid neoplasm in a patient with metastatic melanoma.

Virchows Archiv : an international journal of pathology
2026

Myelodysplastic Syndrome (MDS) With KMT2A::CBL Rapidly Progressed to Acute Myeloid Leukaemia (AML).

EJHaem
2026

An extraction pipeline for analysis of hematopoietic stem cell transplantation data.

Bone marrow transplantation
2026

Effect of RAS Pathway Gene Mutations on Survival in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.

Cancer control : journal of the Moffitt Cancer Center
2026

The role of macrophages and cytokines in the occurrence and development of MDS.

Clinical and experimental medicine
2026

Increased Prevalence of Extrathymic Neoplasms in Myasthenia Gravis Patients-A Population-Based, Matched Case-Control Study.

Muscle &amp; nerve
2026

Therapy of high-risk myelodysplastic syndromes.

Bone marrow transplantation
2026

Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.

The Lancet. Haematology
2026

Severe Hidradenitis Suppurativa and Subsequent Myelodysplastic Syndrome: A Case Report Highlighting Chronic Inflammatory Burden and Carcinogenic Risk.

Cureus
2026

Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS.

Blood
2026

Interpretable Machine Learning to Decipher Myelodysplastic Syndrome-Associated Alterations of the Extracellular Matrix by Time-of-Flight Secondary Ion Mass Spectrometry.

Journal of the American Society for Mass Spectrometry
2026

Secondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustine-rituximab.

Cancer
2026

Whole transcriptome sequencing reveals differences in the pathogenesis of myelodysplastic syndromes and acute myeloid leukemia.

Hematology (Amsterdam, Netherlands)
2026

Clinical and etiological profile of anemia in a clinical hematology department of North Africa : A cross-sectional study.

Leukemia research reports
2026

Diagnostic value of repeat deep sampling and cytocentrifugation in disseminated nocardiosis due to Nocardia brasiliensis with intramuscular and prostatic abscesses in a patient with myelodysplastic syndrome.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
2026

Activity of Ponatinib and Vitamin K2 Against Myelodysplastic Syndrome and Acute Myeloid Leukemia Cells.

Anticancer research
2026

MDM4 HAPLOINSUFFICIENCY LEADS TO P53-MEDIATED BONE MARROW FAILURE.

Blood
2026

Clinical Presentation, Risk Factors and Outcome of Non-Tuberculous Mycobacteria Infection in Hematopoietic Stem-Cell Transplantation: A Multinational Case-Control Study.

Open forum infectious diseases
2026

Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis.

Journal of clinical medicine
2026

RRM1 inhibition sensitizes lung adenocarcinoma to decitabine treatment.

Cell death &amp; disease
2026

Use of Human Intravenous Immunoglobulin Therapy in Two Dogs with Non-Neoplastic Bone Marrow Disorders Refractory to Immunosuppressive Therapy.

Veterinary sciences
2026

Real-World Outcomes of [177Lu]Lu-DOTA-TATE Peptide Receptor Radionuclide Therapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors: Data from a Belgian ENETS Center of Excellence.

Acta gastro-enterologica Belgica
2026

Symptom burden and palliative care in patients with hematologic malignancies: a single-center experience.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
2026

Comparative Analysis of ICC and WHO Classifications Reveals Molecular and Clinical Convergence Between AML-MR and MDS/AML.

Hematological oncology
2026

Beyond initial response: Acquired resistance to hypomethylating agents in myeloid malignancies.

Critical reviews in oncology/hematology
2026

Successful treatment of relapsed FLT3-mutated donor cell-derived MDS/AML with FLT3 inhibitor gilteritinib.

Annals of hematology
2026

Impact of prior solid tumor on outcomes of hematopoietic stem cell transplantation for hematologic malignancies: a propensity score-matched study.

Frontiers in immunology
2026

Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents.

Therapeutic advances in hematology
2026

Symptom burden in patients with hematologic malignancies and its influencing factors.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
2026

Morphologic findings and mutational profiles of myelodysplastic neoplasms with normal versus abnormal karyotype.

Journal of hematopathology
2026

Navigating diagnostic shifts: A comparative review of the WHO 5th edition and ICC 2022 classifications of myeloid neoplasms.

Human pathology
2026

Observational and Genetic Association of Myelodysplastic Syndromes (MDS) and Autoimmune Diseases in Adults.

Mediators of inflammation
2026

Myelodysplastic syndrome progress to acute myeloid leukemia: new insights and updates.

Frontiers in immunology
2026

Potential Clinical Value of Identifying Myelodysplastic Syndrome as a Cardiovascular Risk Condition.

The Canadian journal of cardiology
2026

Extramedullary Hematopoiesis Showing Lymphadenopathy in Myelodysplastic Syndrome without Myelofibrosis.

Internal medicine (Tokyo, Japan)
2026

Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies.

British journal of haematology
2026

Real-world data-based assessment of therapy-related myeloid neoplasms after poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer.

Frontiers in oncology
2026

Acquired Pure Red Cell Aplasia Following BNT162b2 mRNA COVID-19 Vaccination.

Internal medicine (Tokyo, Japan)
2026

Role of SPAG6 in regulating physiological functions and tumorigenesis (Review).

International journal of oncology
2026

Clinical Characteristics and Molecular Profiling of SF3B1-Mutated Myelodysplastic Syndrome (MDS) in a Real-World Practice.

International journal of molecular sciences
2026

Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice.

British journal of haematology
2026

Effectiveness of azacytidine for poly ADP-ribose polymerase inhibitor-induced myelodysplastic syndrome in ovarian cancer patient: a twofold triumph.

Journal of chemotherapy (Florence, Italy)
2026

A CRISPR-Based Humanized Model Reveals Cooperative Role of STAG2 Loss in Familial GATA2-Deficient MDS Progression.

bioRxiv : the preprint server for biology
2026

The development of intrapulmonary shunting caused by luspatercept in low grade myelodysplastic syndrome: a case report.

AME case reports
2026

Early-onset de novo donor-specific anti-HLA antibodies may contribute to poor graft function following haploidentical transplantation for myelodysplastic syndrome: a rare case presentation.

Therapeutic advances in hematology
2026

Mesangial sclerosing glomerulopathy following luspatercept treatment - a case report.

BMC nephrology
2026

T1 mapping on cardiac magnetic resonance of myocardial calcification after septic shock.

Pediatrics international : official journal of the Japan Pediatric Society
2026

[Haploidentical hematopoietic stem cell transplantation for advanced myelodysplastic syndrome patients with recurrent genetic abnormalities].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
2026

Hematological Disease Profile in the Tribal Population of Northern Maharashtra Based on Bone Marrow Examination: A Retrospective Study.

Cureus
2026

Beyond Sweet Syndrome: Untangling the Threads of Histiocytoid Sweet Syndrome and Cutaneous Myeloid Neoplasia.

Surgical pathology clinics
2026

Novel therapies in myeloid neoplasms show limited benefit and increased costs over 15 years of follow-up in Southern Finland.

Annals of hematology
2026

Fatal Ultra-Early-Onset Rhino-Cerebral Mucormycosis Caused by Rhizomucor miehei Following Umbilical Cord Blood Transplantation and Review of Published Literature.

Mycopathologia
2026

Primary Adrenal Insufficiency Due to Recurrent Unilateral Adrenal Infarction in a Patient With Myelodysplastic Syndrome With Isolated del(5q).

AACE endocrinology and diabetes
2026

Anterior Ischemic Optic Neuropathy Associated with Acute Severe Anemia Due to Myelodysplastic Syndrome (MDS): A Case Report.

Neuro-ophthalmology (Aeolus Press)
2026

A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.

Blood
2026

A fatal case of VEXAS syndrome with a brief review.

Journal of vascular surgery cases and innovative techniques
2026

JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.

Leukemia
2025

Clinical perception and novel insights of chronic myelomonocytic leukemia: a 10-year multi-center retrospective study.

Frontiers in medicine
2026

Immunophenotypic abnormality quantification refines multiparameter flow cytometry-based measurable residual disease testing in adults allografted for acute myeloid leukemia in morphologic remission.

HemaSphere
2026

Diffusion-Weighted Magnetic Resonance Imaging and Apparent Diffusion Coefficient Mapping Detect Kidney Infiltration in Acute Myeloid Leukemia: A Case Report.

Kidney medicine
2026

Case series: rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia.

Leukemia &amp; lymphoma
2026

VEXAS syndrome and cancer: Insights about a possible "Tip of the Iceberg". Ambidirectional data from the international AIDA network registries.

Seminars in arthritis and rheumatism
2026

Severe Congenital Neutropenia With Negative Whole-Exome Sequencing Managed With Hematopoietic Stem Cell Transplantation: A Case Report.

Cureus
2026

Myelodysplastic syndrome with cryptic 5q deletions in young male patients showing sustained response to lenalidomide.

Haematologica
2026

Transferability of Real World Evidence to Support HTA Recommendations in Lower Income European Countries.

Health science reports
2026

Aberrant CD25 and Increased CD123 Expression Are Common in Acute Myeloid Leukemia with KMT2A Partial Tandem Duplication and Are Associated with FLT3 Internal Tandem Duplication.

Cancers
2026

Marrow Microenvironmental Pathobiology and Therapeutic Opportunities for TP53-Mutated Myelodysplastic Syndrome/Acute Myeloid Leukemia.

Cancers
2026

Moving Beyond Somatic Alterations: Uncovering the Germline Basis of Myeloid Malignancies.

Cancers
2026

Subsequent Neoplasms After Umbilical Cord Blood Transplantation in the Japanese and European Populations.

Transplantation and cellular therapy
2026

Diagnostic pitfalls of ESA-resistant anemia due to functional copper deficiency in a dialysis patient: a myelodysplastic syndrome mimic.

CEN case reports
2026

Successful Treatment of Refractory Sweet's Syndrome With Adalimumab in a Myelodysplastic Syndrome Patient.

EJHaem
2026

Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records.

EClinicalMedicine
2026

Passenger Lymphocyte Syndrome in Pediatric Lung Transplantation: A Recipient With Previous Hematopoietic Stem Cell Transplantation.

Pediatric transplantation
2026

In vivo CRISPR screening identifies SAGA complex members as key regulators of hematopoiesis.

Nature communications
2026

Novel Genomic Biomarkers Improve Post-Hematopoietic Cell Transplantation Relapse Risk Stratification for Patients With Myelodysplastic Syndromes.

JCO precision oncology
2026

International Prognostic Scoring System, Revised International Prognostic Scoring System, and Molecular International Prognostic Scoring System Had No Identical Prognostic Power Depending on Treatment in Myelodysplastic Syndromes.

Acta haematologica
2026

Intensification of Treosulfan-Fludarabine Conditioning With Thiotepa Exhibited Effectiveness and Tolerability in Older or Comorbid Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant With Active Myeloid Neoplasm: A Real-world Study.

Transplantation direct
2026

Synergistic apoptosis induction in myelodysplastic syndrome cells by azacitidine and PIM-2 inhibitors via nuclear factor-kappa B pathway inhibition.

BMC cancer
2026

Prediction of myeloid malignant cells in Fanconi anemia using machine learning.

PloS one
2026

Cancer risk in patients with pulmonary fibrosis and a rare telomere related gene variant.

Respiratory research
2026

Autoimmune HLA alleles and neoantigens predict myelodysplastic syndrome outcomes after allogeneic HSCT: A CIBMTR analysis.

iScience
2026

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study.

American journal of hematology
2026

A case of paraneoplastic unilateral leg swelling in myelodysplastic syndrome preceding transformation to acute myeloid leukemia and responding to IL-1 inhibition.

The American journal of medicine
2026

Successful treatment of probable disseminated mucormycosis using liposomal amphotericin B and isavuconazole in myelodysplastic syndrome: A case report and literature review.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
2026

Anemia Contributes to, But Does Not Explain, Cardiovascular Disease Risk Enhancement in Patients With Myelodysplastic Syndrome.

The Canadian journal of cardiology
2026

FBXO11 suppression rewires an NPM1-centered interactome influencing the progression of myelodysplastic syndrome.

The Journal of clinical investigation
2026

Sustained response to minimal-dose tagraxofusp in a patient with BPDCN and advanced chronic kidney disease.

Annals of hematology
2026

Podocytic Infolding Gromerulopathy Developed at the Time of Transition from Chronic Myelogenous Leukemia to Myelodysplastic Syndrome: A Case Report.

Internal medicine (Tokyo, Japan)
2026

A Rare Manifestation of Cardiac Myeloid Sarcoma.

JACC. Case reports
2026

Acyclovir-Resistant Herpes Simplex Virus in Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Case Series.

Transplant infectious disease : an official journal of the Transplantation Society
2026

More than CLK bait? Rogocekib for MDS and AML.

Blood advances
2025

[Treatment goals for low-risk myelodysplastic syndromes].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2026

Behçet-like intestinal disease in a patient with trisomy 8-associated myelodysplastic syndrome (TRIAD).

BMJ case reports
2026

A Yeast-Based High-Throughput Screening Platform for the Discovery of Novel pre-mRNA Splicing Modulators.

ACS chemical biology
2025

Febrile Neutropenia in the Context of Clozapine-Induced Agranulocytosis (CIA) and Myelodysplastic Syndrome: Importance of a Multidisciplinary Approach.

Cureus
2026

Myelodysplastic Syndrome With Complex Chromosomal Karyotype Abnormalities Complicated by Multiple Intestinal Perforations: A Case Report and Literature Review.

Case reports in gastrointestinal medicine
2025

Diagnostic and Prognostic Significance of miR-155, miR-181, miR-221, miR-222, and miR-223 Expression in Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Diagnostics (Basel, Switzerland)
2026

Impact of thrombosis and bleeding on survival of older people with myelodysplastic syndromes: a population analysis.

Journal of thrombosis and haemostasis : JTH
2026

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.

EClinicalMedicine
2025

[The Effect of Serum Ferritin before Transplantation on Implantation in MDS and AML Patients after Unrelated Cord Blood Transplantation].

Zhongguo shi yan xue ye xue za zhi
2025

[The Role of MiR-709 in Erythroid Development and Its Correlation with Multiple Hematological Diseases].

Zhongguo shi yan xue ye xue za zhi
2025

[Correlation between ASXL1 Gene Mutation Characteristics and Clinical Manifestations and Prognosis in Patients with Myelodysplastic Syndrome].

Zhongguo shi yan xue ye xue za zhi
2026

Hematologic Landscape of Adult Patients With Diamond-Blackfan Anemia Syndrome.

American journal of hematology
2025

The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells.

bioRxiv : the preprint server for biology
2025

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China.

EClinicalMedicine
2026

Navigating prognostic stratification and approach to TP53 -mutated myeloid neoplasms.

Current opinion in hematology
2025

Oral Squamous Cell Carcinoma in a Patient with Myelodysplastic Syndrome: Report of a Case and Literature Review.

Frontiers in dentistry
2026

Hetrombopag Added to Cyclosporine as the First-Line Treatment for Patients With Non-Severe Aplastic Anemia: A Phase 2 Multicenter Trial.

American journal of hematology
2026

Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.

British journal of haematology
2026

MDSC subpopulation dynamics predict disease evolution: a multidimensional biomarker framework for risk assessment in MDS.

Clinical and experimental medicine
2026

A Case of VEXAS Syndrome Initially Masked as Myelodysplastic Syndrome: Importance of Marrow Vacuolization and UBA1 Testing: A Case Report.

The American journal of case reports
2025

Periprosthetic Solitary Fibrous Tumor of the Proximal Femur: A Case Report.

JBJS case connector
2025

Spontaneous Resolution of Unexplained Neutropenia in Primary Hyperparathyroidism: A Case Report.

Cureus
2025

Isavuconazole for the Treatment of Invasive Fungal Disease in Hematology Patients: A Real-World Retrospective Study on Efficacy and Safety.

Microorganisms
2025

Clinical Utility of Multiplex Ligation-Dependent Probe Amplification in the Genetic Assessment of Patients with Myelodysplastic Syndrome.

Biomedicines
2025

Cytogenetic Abnormalities in Pediatric Myelodysplastic Syndrome: Insights on the Disease Biology and Impact on Leukemic Evolution.

Biomedicines
2025

RUNX1-FPDMM in families with mild thrombocytopenia and platelet function anomalies: a case series.

Frontiers in medicine
2026

Polychondritis revealing the acutisation of myelodysplasia into acute myeloid leukaemia in a 36-year-old woman: A case report.

Joint bone spine
2026

Congenital Myelodysplastic Syndrome in a Newborn With Germline JAK2 Variant Treated With Liposomal Cytarabine-Daunorubicin and Allogeneic Hematopoietic Stem Cell Transplant.

Pediatric blood &amp; cancer
2025

[Outcome of clinical follow-up of maternal malignant tumors indicated by abnormal NIPT signals].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2026

SF3B1 mutations in spliceosome-driven tumorigenesis: From splicing dysregulation to signaling network rewiring and therapeutic targeting.

Biochimica et biophysica acta. Reviews on cancer
2025

Inquiry Regarding the Impact of Anemia Adjustment on Cardiovascular Disease Risk in Patients With Myelodysplastic Syndrome.

The Canadian journal of cardiology
2026

Polycomb repressive complexes as therapeutic targets in hematologic malignancies.

Experimental hematology
2025

A Case Series of SGLT2i Improving Hemoglobin in Adults with Myelodysplastic Syndrome.

Acta haematologica
2026

A proposal for expedited stem cell transplantation for TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.

Blood advances
2026

Review of flow cytometry findings and associated scoring approaches for identifying myelodysplastic syndrome and the future role of machine learning in improving the diagnostic algorithm.

American journal of clinical pathology
2025

Clinical and Biological Insights into Myelodysplastic Neoplasms Associated with Deletions of Chromosome 5q Region.

Hematology reports
2025

Treatment of Relapsed/Refractory t(11;14) Multiple Myeloma and High-Risk Myelodysplastic Syndrome With Venetoclax.

Case reports in hematology
2025

Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.

British journal of haematology
2025

Isolated KRAS and NRAS mutations in adults with monocytosis and/or cytopenia(s).

Haematologica
2025

A novel GATA1 variant linking germline and somatic myelodysplastic syndrome in two patients.

Haematologica
2025

The effects of adding decitabine to conditioning regimen for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.

Annals of hematology
2026

Impact of Germline CHEK2 Pathogenic Variants on the Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
2025

Minoxidil ameliorates myelodysplastic syndrome by targeting Wnt4 while sparing normal hematopoiesis.

Cell communication and signaling : CCS
2026

Dynamic and extensive A-to-I RNA recoding in immunoglobulin shapes myeloid neoplasm transcriptome.

The Journal of biological chemistry
2025

Molecular Characterization of <italic>MECOM</italic> Rearrangements in Two Cases with Myelodysplastic Syndrome and t(2;3)(p23;q26.2).

Cytogenetic and genome research
2025

Shared donor-recipient γδ T-cell phenotypic and repertoire features associate with cytomegalovirus reactivation after allogeneic haematopoietic stem cell transplantation.

Clinical &amp; translational immunology
2026

Cyclosporine A improves survival in lower-risk hypoplastic myelodysplastic syndromes: a single-center retrospective study from China.

Hematology (Amsterdam, Netherlands)
2025

VEXAS syndrome in rheumatology practice: features from a multicenter cohort in north-east Italy.

Frontiers in immunology
2025

A multicenter, prospective, non-interventional drug intensive monitoring study of olaparib in a large real-world Chinese patient cohort with ovarian cancer (DIM-OC).

Journal of ovarian research
2025

Immature platelet fraction and bone marrow findings in hematology.

Scientific reports
2025

[Impact of donor characteristics on prognosis for myelodysplastic syndromes after haplo-identical transplantation: a retrospective study].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
2025

[Myelodysplastic neoplasms with acute myeloid leukemia-like mutations: clinical features, molecular profiles, and prognosis].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
2025

SF3B1K700E mutation in human embryonic stem cells causes aberrant expression of immune-related genes.

PloS one
2026

Myelodysplastic/Myeloproliferative Neoplasm in a Dog: A Case Report.

Veterinary medicine and science
2025

Asymptomatic Nasopharyngeal Myeloid Sarcoma Presenting With Cervical Lymphadenopathy: A Case Report.

Ear, nose, &amp; throat journal
2025

[VEXAS syndrome mimicking relapsing polychondritis: A case report].

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
2025

Triptolide combined with arsenic trioxide induces apoptosis of myelodysplastic syndrome cells by inhibiting the NF-κB signaling pathway.

Medicine
2025

Higher HLA-DRB1 Evolutionary Divergence Is Associated with Reduced Relapse and Improved Survival after Matched Unrelated Hematopoietic Cell Transplantation.

Transplantation and cellular therapy
2026

One train can hide another one, a case of myelodysplastic syndrome (MDS) and splenic diffuse red pulp small B cell lymphoma (SDRPL).

Annales de biologie clinique
2025

Therapy related myelodysplastic syndrome: a hematologic sequela of low dose methotrexate in rheumatoid arthritis.

Oxford medical case reports
2025

A Massive Haemothorax Due to Pleural Extramedullary Haematopoiesis in a Patient With Myelodysplastic Syndrome/Myeloproliferative Neoplasm.

Cureus
2026

Safety and effectiveness of the combination of 5-azacitidine and ruxolitinib in VEXAS syndrome: A single-centre experience.

British journal of haematology
2025

Ribosomal protein control of hematopoietic stem cell transformation through regulation of metabolism.

Cell reports
2026

Telomere length as a prognostic biomarker in myelodysplastic syndrome treated with hypomethylating agents.

Leukemia &amp; lymphoma
2026

Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.

Blood
2025

The impact of the number and the size of clusters on prediction performance of the stratified and the conditional shared gamma frailty Cox proportional hazards models.

medRxiv : the preprint server for health sciences
2025

FDA approval of imetelstat: a new era in the treatment of lower-risk myelodysplastic syndrome.

Annals of medicine and surgery (2012)
2025

Remimazolam-Based Anesthetic Management in a Patient with Severe Aortic Stenosis and Myelodysplastic Syndrome-Related Thrombocytopenia: A Case Report.

Journal of clinical medicine
2025

Droplet Digital PCR Outperforms Conventional Methods for Early Relapse Prediction in Acute Myeloid Leukemia/Myelodysplastic Syndrome Patients Post-Transplantation.

Transplantation and cellular therapy
2025

Synergy in Immunostimulatory and Pro-Differentiation Effects of Vitamin D Analog and Fludarabine in Acute Myeloid Leukemias.

Cells
2025

Therapy-related Myeloid Neoplasms After Autologous Stem Cell Transplantation for Lymphoma: A Single-Center Experience.

Blood cell therapy
2025

Preparing for allogeneic hematopoietic stem cell transplant: a multidisciplinary prehabilitation intervention is safe, feasible and demonstrates preliminary efficacy in acute myeloid leukemia and myelodysplastic syndromes.

BMC cancer
2025

Integrative Multi-Omics Analysis Unveils the Molecular Mechanisms by Which TP53 Mutation Influence Early Decitabine Resistance in Myelodysplastic Syndrome.

Journal of cellular biochemistry
2026

Acute severe cholestatic hepatitis and lymphopenia characterize pediatric hepatitis-associated aplastic anemia.

Journal of pediatric gastroenterology and nutrition
2025

[Allogeneic hematopoietic stem cell transplantation with high-dose melphalan and total body irradiation for hematological malignancies: a single-center retrospective analysis].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2025

Post Hematopoietic Cell Transplantation Maintenance Therapy With Low-Dose Azacitidine in a Pediatric Population With High-Risk Myeloid Malignancies.

Transplantation and cellular therapy
2025

Outcomes of fludarabine-melphalan versus fludarabine-busulfan reduced-intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A systematic review and meta-analysis.

Cancer
2025

Real-world incidence and risk of myelodysplastic syndrome and acute myeloid leukemia secondary to PARP inhibitors in ovarian cancer.

Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
2026

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.

Blood advances
2025

Updates in low/intermediate-risk MDS.

Hematology. American Society of Hematology. Education Program
2025

Management of iron overload in adult myelodysplastic syndrome.

Hematology. American Society of Hematology. Education Program
2025

VEXAS Syndrome Presenting With Pleuritis.

Clinical case reports
2025

Case Report: Secondary myelodysplastic syndrome following autologous stem cell transplantation in a patient with POEMS syndrome.

Frontiers in immunology
2025

[Methodological appraisal of statistical approaches to evaluating the impact of chronic graft-versus-host disease on mortality after hematopoietic stem cell transplantation].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
2026

Demand for human leukocyte antigen or human platelet antigen-selected platelets: An observational study at Canadian Blood Services.

Transfusion
2025

Collapsing Glomerulopathy in a Patient With Myelodysplastic Syndrome With Isolated del(5q): A Case Report.

Kidney medicine
2026

Individualized Treosulfan-Based Conditioning Improves Outcomes of Allogeneic Hematopoietic Transplantation for Myelodysplastic Syndrome: A 25-Year Retrospective, Population-Based Analysis.

Transplantation and cellular therapy
2025

TMEM91::TAL1 Fusion gene in a middle-aged female with rapid MDS to secondary AML progression: a case report.

Hematology (Amsterdam, Netherlands)
2025

Chromatin accessibility in stem cells unveils progressive transcriptional alterations in myelodysplastic syndrome.

Nature communications
Ver todos os 6.634 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndromes mielodisplásicos.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Síndromes mielodisplásicos

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. RNF25 confers mRNA damage tolerance by curbing activation of the integrated stress response.
    Molecular cell· 2026· PMID 41875887mais citado
  2. Impact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.
    Transplantation and cellular therapy· 2026· PMID 41864573mais citado
  3. Effect of Somatic Variants Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome.
    Hematology/oncology and stem cell therapy· 2026· PMID 41846455mais citado
  4. Aberrant Kupffer-like differentiation of hematopoietic stem cell is critical for the MDS pathogenesis in Setd2-deficient mice.
    Cell death and differentiation· 2026· PMID 41844896mais citado
  5. Application of next-generation sequencing in the treatment of myelodysplastic syndrome: from mechanisms to clinical practice.
    Blood science (Baltimore, Md.)· 2026· PMID 41821552mais citado
  6. Health-related quality of life of patients with acute myeloid leukemia and myelodysplastic syndromes/neoplasms treated with decitabine: a systematic literature review.
    Ann Hematol· 2026· PMID 41995852recente
  7. Concurrent SF3B1 Mutation and BCR::ABL1 Demonstrating a Myelodysplastic Syndrome Phenotype: A Case Report.
    EJHaem· 2026· PMID 41994083recente
  8. Behçet's syndrome-like features revealing myelodysplastic syndrome with TP53 mutation: a case report.
    Front Immunol· 2026· PMID 41993159recente
  9. Disparities in blood cancer survival in the UK 2009-2019: national cohort studies.
    BJC Rep· 2026· PMID 41986693recente
  10. Luspatercept: From Bench to Bedside and Beyond in the Management of Ineffective Erythropoiesis.
    J Hematol· 2026· PMID 41983155recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:52688(Orphanet)
  2. OMIM OMIM:614286(OMIM)
  3. MONDO:0018881(MONDO)
  4. GARD:7132(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)
  8. Q954625(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Síndromes mielodisplásicos
Compêndio · Raras BR

Síndromes mielodisplásicos

ORPHA:52688 · MONDO:0018881
Prevalência
1-9 / 100 000
CID-10
D46 · Síndromes mielodisplásicas
Ensaios
30 ativos
Início
All ages
Prevalência
7.0 (Germany)
MedGen
UMLS
C0026985
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades